3 completed. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 1 | 1 | Completed 1 |
Follow Choroidal Effusions: new trials by email Literature Review of Choroidal Effusions trials Research Report on Choroidal Effusions
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration CLS-AX, Aflibercept - Neovascular Age-related Macular Degeneration | Phase 2 | Completed | Clearside Biomedical, Inc. | 60 | 2023-05-31 | 2025-07-25 |
| Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis 4 mg CLS-TA, 0.8 mg CLS-TA - Uveitis, Macular Edema | Phase 2 | Completed | Clearside Biomedical, Inc. | 22 | 2014-10-01 | 2021-02-08 |
| Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis triamcinolone acetonide (Triesence®) - Uveitis, Intermediate Uveitis | Phase 1 / Phase 2 | Completed | Clearside Biomedical, Inc. | 11 | 2013-02-01 | 2021-02-21 |
Panuveitis (2) · Uveitis (2) · Uveitis, Intermediate (2) · Uveitis, Posterior (2) · Giant Cell Arteritis (1) · Inflammation (1) · Macular Edema (1) · Ophthalmia, Sympathetic (1) · Uveitis, Anterior (1)
Choroid Diseases (3) · Eye Abnormalities (3) · Eye Diseases (3) · Uveal Diseases (3) · Arteritis (1) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Brain Diseases (1) · Cardiovascular Diseases (1) · Central Nervous System Diseases (1) · Cerebrovascular Disorders (1) · Immune System Diseases (1) · Macular Degeneration (1) · Nervous System Diseases (1) · Pathologic Processes (1)
Adrenal Cortex Hormones (1) · Triamcinolone (1) · Triamcinolone Acetonide (1) · aflibercept (1)
Clearside Biomedical, Inc. (3)
United States (3)
Thomas Ciulla, MD (2) · Susan Coultas, PhD (1)